Saturday 17 October 2026 Export RDNT’s income statement to Excel — free account

RadNet, Inc.

RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 25.0%, EPS fell 47.4%, free cash flow fell 43.2% and total debt rose 21.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

68.53 1.88 −2.67%

Follow RDNT

Alert me

Market cap: $5.5B
P/E: 0.0×
Fwd P/E: 279×
Dividend yield: —
F-score: 3/9
Altman Z: 2.04
Beneish M: −2.62
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.35

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	—	—	1	—	—	3	—	—	—	—

Insider Ownership 9.47%

Capital & Financial Ratios $m

Market Cap 5,540.00

Revenue 2,268.93

Net Income 19.27

Free Cash Flow 74.36

Net Debt 579.88

Current Ratio 1.48

Debt/Equity 0.94

P/E ratio 0.00

Fwd P/E 279.00

P/S ratio 2.35

P/B ratio 3.82

Past 5Y EPS Growth —

This Y EPS Growth 31.87%

Next Y EPS Growth 72.41%

Next Y revenue growth 22.88%

Next 5Y EPS Growth 41.72%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 85.29%

10-year low 10-year high

P/B against its own 10 years 44.75%

10-year low 10-year high

EV/Sales against its own 10 years 86.33%

10-year low 10-year high

EV/FCF against its own 10 years 85.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	343	740	767	726
Receivables	164	186	200	242
Inventory	—	—	—	—
Other	25	42	13	7
	579	1,019	1,032	1,036

	2023	2024	2025	Q'26
Payables	343	351	422	490
ST’ Debt	—	25	25	—
Other	16	44	70	91
	437	480	587	698

Compound Annual Growth %

	10y	5y	3y
Sales	9.68%	13.74%	12.57%
Cash Flow	16.12%	5.03%	26.84%
Earnings	0.00%	0.00%	0.00%
Book Value	43.56%	39.32%	40.25%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	576	623	—	—	—
’25	471	498	523	548	2,040
’24	432	460	461	477	1,830
’23	391	404	402	420	1,617
’22	342	354	350	384	1,430
’21	315	334	333	333	1,315
’20	282	191	292	308	1,072

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	79	94	—	—	—
’25	41	120	53	84	299
’24	17	116	57	43	233
’23	33	68	31	89	221
’22	1	65	27	54	146
’21	28	31	42	49	149
’20	41	91	39	63	234

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	38	—	—	—
’25	(7)	67	(8)	34	87
’24	(40)	69	16	0	45
’23	(23)	29	(21)	49	44
’22	(36)	33	(26)	34	31
’21	(2)	8	(63)	65	7
’20	(10)	78	26	47	140

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.43)	0.10	—	—	—
’25	(0.50)	0.19	0.07	(0.01)	(0.25)
’24	(0.04)	(0.04)	0.04	0.07	0.04
’23	(0.36)	0.12	0.25	(0.03)	0.05
’22	0.05	0.13	0.01	(0.02)	0.17
’21	0.18	0.05	0.30	(0.07)	0.46
’20	(0.33)	(0.21)	0.12	0.11	(0.29)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.66	5.25	9.65	9.97	5.81	17.68	12.03	17.82	33.44	45.00	Analyst estimates 2026–2028 Powerpack
	High	7.98	11.90	16.54	20.45	23.45	38.84	30.43	37.97	93.65	85.84
People
People	Employees	7,285	7,440	7,869	8,498	8,327	8,973	9,067	10,288	11,021	11,264
	Revenue/emp, $m	0.12	0.12	0.12	0.14	0.13	0.15	0.16	0.16	0.17	0.18
Income, $m
Income, $m	Revenue	885	922	975	1,154	1,072	1,315	1,430	1,617	1,830	2,040
	Gross margin, %	12.29	12.99	11.03	13.39	9.88	14.58	11.59	13.69	13.62	11.54
	EBT	12	26	39	30	(1)	59	43	39	45	32
	EBT margin, %	1.41	2.86	3.95	2.57	(0.08)	4.48	3.00	2.40	2.45	1.56
	Net income	8	2	38	23	(2)	44	34	30	39	17
	Depreciation	72	70	77	152	163	178	191	196	211	217
Per share, $
Per share, $	Revenue	19.13	19.67	20.27	23.23	21.06	25.05	25.40	25.43	25.05	27.13
	Earnings	0.16	0.00	0.67	0.30	(0.29)	0.47	0.19	0.05	0.04	(0.25)
	Cash flow	1.98	3.03	2.43	2.10	4.59	2.85	2.60	3.47	3.19	3.97
	Capex	(1.26)	(1.28)	(1.44)	(1.47)	(1.83)	(2.71)	(2.05)	(2.78)	(2.57)	(2.82)
	Free cash flow	0.72	1.75	0.99	0.63	2.76	0.14	0.55	0.70	0.62	1.16
	Book value	1.13	1.49	4.16	4.69	5.08	6.59	8.73	12.79	15.52	18.03
	Shares, m	46	47	48	50	51	52	56	64	73	75
Valuation, ×
Valuation, ×	P/E	36.89	0.00	15.41	70.00	0.00	64.06	103.56	3,456.00	2,328.00	0.00
	P/S	0.34	0.51	0.50	0.87	0.93	1.20	0.73	1.36	2.79	2.63
	P/B	5.77	6.74	2.44	4.33	3.86	4.57	2.14	2.70	4.50	3.96
	EV/Sales	1.01	1.08	1.14	1.50	1.51	1.72	1.28	1.70	2.94	2.79
	EV/FCF	26.89	12.10	23.46	55.16	11.51	185.15	59.31	1,196.26	1,759.54	126.94
Cash, $m
Cash, $m	Operating cash flow	92	142	117	104	234	149	146	221	233	299
	Capex	(58)	(60)	(69)	(73)	(93)	(142)	(116)	(177)	(188)	(212)
	Free cash flow	33	82	47	31	140	7	31	44	45	87
Balance, $m
Balance, $m	Working capital	63	44	(31)	(86)	(128)	(51)	(100)	142	540	445
	Total debt	639	609	672	760	722	820	909	812	1,016	1,090
	Net debt	619	558	662	720	620	686	782	469	276	323
	Shareholders’ equity	52	70	200	233	258	346	491	813	1,133	1,356
Returns, %
Returns, %	ROA	0.86	0.01	3.26	1.07	(0.86)	1.29	0.47	0.12	0.09	(0.53)
	ROIC	3.59	4.98	2.24	4.58	2.54	5.00	2.28	4.81	4.64	2.31
	ROE	16.34	0.09	23.87	6.81	(6.04)	8.18	2.54	0.47	0.29	(1.50)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QGEN QIAGEN N.V.	$9.5B	23.6×	17.5×	+0.28% (above 0%: growing)	+7.94% (above 0%: growing)	+30.45% (above 0%: growing)	63.62%	24.75%	Compare
TWST Twist Bioscience Corporation	$9.5B	— (loss-making)	— (loss-making)	+23.24% (above 0%: growing)	n/m	−7.23% (below 0%: shrinking)	52.76%	(30.65%)	Compare
GRAL GRAIL, Inc.	$6.1B	— (loss-making)	— (loss-making)	+25.72% (above 0%: growing)	n/m	−4.95% (below 0%: shrinking)	(28.12%)	(388.89%)	Compare
RDNT RadNet, Inc.	$5.5B	— (loss-making)	279×	+24.99% (above 0%: growing)	−47.37% (below 0%: shrinking)	−43.22% (below 0%: shrinking)	14.14%	6.34%
SHC Sotera Health Company	$5.2B	31.4×	23.7×	+9.18% (above 0%: growing)	+533.33% (above 0%: growing)	+60.56% (above 0%: growing)	55.38%	33.23%	Compare
BLLN BillionToOne, Inc.	$4.9B	95.0×	99.4×	+64.40% (above 0%: growing)	n/m	+400.65% (above 0%: growing)	70.45%	5.03%	Compare
ADPT Adaptive Biotechnologies Corporation	$4.1B	— (loss-making)	— (loss-making)	+21.53% (above 0%: growing)	n/m	+42.04% (above 0%: growing)	71.82%	(22.04%)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
Median of peers	$5.0B	29.9×	45.1×	+22.39%	—	+37.50%	67.04%	10.16%

All 52 Diagnostics & Research stocks →

RadNet, Inc. (RDNT) key facts

Strength: RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
RadNet, Inc. (RDNT) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RDNT traded at $68.53, a market capitalization of $5.5 billion.
Return on equity was −1.50% and debt-to-equity 0.94.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 2.04 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.